The importance of long-term follow-up in patients from clinical trials

International MS Journal

Volumn 9, Issue 3, 2002, Pages 76-78

  Paty, Donald W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON BETA SERINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE DURATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MEGADOSE; DRUG SCREENING; DRUG TOLERABILITY; EDITORIAL; FOLLOW UP; HUMAN; LONG TERM CARE; MEDICAL INFORMATION; MULTIPLE SCLEROSIS; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0036444061     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (19)

1. IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294.
3. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1A in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
4. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo controlled multicentre randomised trials of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.
5. Li DK, Zhao GJ, Paty DW for the SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. MRI results. Neurology 2001; 56: 1505-1513.
6. Johnson KP, Brooks BP, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
7. The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628-1636.
8. Kobelt G, Jonsson L, Miltenburger C, Jonsson B. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Assess Health Care 2002; 18: 127-138.
9. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701-708.
10. Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up. J Interferon Res 1993; 5: 333-340.
11. Karlik K, Kirk S, Nicolle E, Kremenchutzky M, Rice GPA. Evidence for very long term MRI efficacy of interferon beta 1b in relapsing remitting MS patients. Mult Scler 2001; 7 (Suppl 1): S52.
12. Horowski R, Sturzbecher C-S, Kapp J-K. Neutralizing antibodies and interferon beta-1b therapy of multiple sclerosis. Funct Neurol 2001; 16: 117-128.
13. Rice GPA, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999; 52: 1277-1279.
14. Pryce-Philips W. Ethical considerations for clinical trial design in MS. Int MS J 2002; 9: 8-15.
15. Oger J, Gibbs E. Studies of interferon beta-1b binding antibodies in treated MS patients. Mult Scler 2001; 7 (Suppl 1): S101.
16. Paty DW, Boiko AN. Beta-interferons delay the switch from relapsing-remitting to secondary progressive multiple sclerosis. Neurology 2000; 54: A337.
17. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419-1428.
18. Ebers GC, Koopman WJ, Hader W, Sadovnick AD, Kremenchutzky M, Mandalfino P et al. The natural history of multiple sclerosis: A geographically based study. 8: Familial multiple sclerosis. Brain 2000; 123: 641-649.
19. Sylvia Lawry Centre for Multiple Sclerosis Research. Information available at: www.slcmsr.org/en/index.htm (accessed 19 August 2002).